MRE v IUS needs a large multi centre study after Rx in transmural SB CD to change clinical practice. Reflecting on 25 years of IBD practice across 🇮🇳 and 🇬🇧 enthusiasts push one or the other technology. Maybe we end up agreeing that both are equally good!!
Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn’s Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial 👇 https://t.co/bYHwJtKgh2 #Vedolizumab #Gastroenterology #CrohnsDisease
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
RT @ibddoctor: MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26…
MRE could be a noninvasive endpoint in transmural CD if we can get everyone back for repeated scans; N=27 at baseline and 26 weeks, N=13 at weeks 26 and 52 in this study. https://t.co/6BXofKr9Db